Total Funding
41
64
Total FundingPost-IPO Equity raised
Growth Score 41 in past quarter
-11 pts
Heat Score 64 in past quarter
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
77493
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
- Kevin Lee: Chief Executive OfficerPast Role: Pfizer, CSO, Orphan and Genetic Diseases
- Nick Keen: Chief Scientific Officer
About the Company
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.
The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

